The next seminar from the NHLI’s Inflammation, Repair and Development Section comes from Dr Sarah Gilpin who is a Principal Scientist in Tissue Systems (Organ Manufacturing Group) at Lung Biotechnology, PBC, United Therapeutics.
Her expertise and professional focus has been concentrated on understanding the mechanisms of lung disease, regeneration, and tissue repair. Sarah performed her PhD at the University of Toronto, under the guidance of Dr Thomas Waddell after which she did a postdoc in Pulmonary tissue engineering and regeneration at the Harvard Medical School and later worked as a Senior Scientist in the Organ Chip-Enabled Technologies group led by Dr Donald Ingber at the Wyss Institute. Sarah has developed a vast array of expertise focused on pulmonary pathology, transplantation biology, stem cell biology, regenerative medicine and ex vivo models of disease, and bioengineering and her work has led to a record of research accomplishments and product development. Sarah has also managed numerous teams and multiple projects in the Organ and Chip technology groups including cystic fibrosis modelling and infection in the upper airway and infuenza and coronavirus infection and therapeutic discovery.